Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinics |
Texto Completo: | https://www.revistas.usp.br/clinics/article/view/96916 |
Resumo: | OBJECTIVES: Despite its rising popularity, reports on the use of preoperative imatinib mesylate (IM) in patients with advanced gastrointestinal stromal tumor (GIST) are limited. This study aims to explore the clinical efficacy of preoperative IM in patients with primarily unresectable or metastatic/recurrent GIST. METHODS: Between September 2009 and February 2014, patients with primarily unresectable or metastatic/recurrent GIST treated by a single medical team were recruited and considered for preoperative IM therapy. Re-examination was conducted regularly and abdominal enhanced CT data, blood biochemistry and responses to IM were recorded. RESULTS: A total of 18 patients were enrolled, including 13 with a primary tumor (7 stomach, 3 small bowel, 2 rectal and 1 pelvic tumor) and 5 with recurrent or metastatic GIST (2 with liver metastasis, 2 with anastomotic recurrence and 1 with pelvic GIST). The median follow-up time was 9.5 months (range of 3-63). The median tumor sizes before and after initiation of IM treatment were 9.1 cm and 6.0 cm (p = 0.003) based on the CT findings, respectively. All patients showed a decrease in tumor burden and the median tumor size reduction was 35%. Sixteen of the 18 patients showed a partial response to IM and two possessed stable disease. Nine of the 18 patients (50%) underwent surgical resection of primary or metastatic/recurrent tumors, with a median of 7 months of IM therapy. One case each of multivisceral resection and tumor recurrence were noted. CONCLUSIONS: IM as a preoperative therapy is feasible and safe for unresectable or metastatic/recurrent GIST that can effectively decrease tumor size, facilitating resection. |
id |
USP-19_33f7ffd1309dca89bef6b4c9328d0fb0 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/96916 |
network_acronym_str |
USP-19 |
network_name_str |
Clinics |
repository_id_str |
|
spelling |
Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor OBJECTIVES: Despite its rising popularity, reports on the use of preoperative imatinib mesylate (IM) in patients with advanced gastrointestinal stromal tumor (GIST) are limited. This study aims to explore the clinical efficacy of preoperative IM in patients with primarily unresectable or metastatic/recurrent GIST. METHODS: Between September 2009 and February 2014, patients with primarily unresectable or metastatic/recurrent GIST treated by a single medical team were recruited and considered for preoperative IM therapy. Re-examination was conducted regularly and abdominal enhanced CT data, blood biochemistry and responses to IM were recorded. RESULTS: A total of 18 patients were enrolled, including 13 with a primary tumor (7 stomach, 3 small bowel, 2 rectal and 1 pelvic tumor) and 5 with recurrent or metastatic GIST (2 with liver metastasis, 2 with anastomotic recurrence and 1 with pelvic GIST). The median follow-up time was 9.5 months (range of 3-63). The median tumor sizes before and after initiation of IM treatment were 9.1 cm and 6.0 cm (p = 0.003) based on the CT findings, respectively. All patients showed a decrease in tumor burden and the median tumor size reduction was 35%. Sixteen of the 18 patients showed a partial response to IM and two possessed stable disease. Nine of the 18 patients (50%) underwent surgical resection of primary or metastatic/recurrent tumors, with a median of 7 months of IM therapy. One case each of multivisceral resection and tumor recurrence were noted. CONCLUSIONS: IM as a preoperative therapy is feasible and safe for unresectable or metastatic/recurrent GIST that can effectively decrease tumor size, facilitating resection. Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2014-11-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/9691610.6061/clinics/2014(11)09Clinics; Vol. 69 No. 11 (2014); 758-762Clinics; v. 69 n. 11 (2014); 758-762Clinics; Vol. 69 Núm. 11 (2014); 758-7621980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/96916/95996Copyright (c) 2015 Clinicsinfo:eu-repo/semantics/openAccessShen, Chaoyong Chen, Haining Yin, Yuan Chen, Jiaju Zhang, Bo Chen, Zhixin Chen, Jiaping 2015-03-27T18:21:03Zoai:revistas.usp.br:article/96916Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2015-03-27T18:21:03Clinics - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor |
title |
Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor |
spellingShingle |
Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor Shen, Chaoyong |
title_short |
Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor |
title_full |
Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor |
title_fullStr |
Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor |
title_full_unstemmed |
Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor |
title_sort |
Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor |
author |
Shen, Chaoyong |
author_facet |
Shen, Chaoyong Chen, Haining Yin, Yuan Chen, Jiaju Zhang, Bo Chen, Zhixin Chen, Jiaping |
author_role |
author |
author2 |
Chen, Haining Yin, Yuan Chen, Jiaju Zhang, Bo Chen, Zhixin Chen, Jiaping |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Shen, Chaoyong Chen, Haining Yin, Yuan Chen, Jiaju Zhang, Bo Chen, Zhixin Chen, Jiaping |
description |
OBJECTIVES: Despite its rising popularity, reports on the use of preoperative imatinib mesylate (IM) in patients with advanced gastrointestinal stromal tumor (GIST) are limited. This study aims to explore the clinical efficacy of preoperative IM in patients with primarily unresectable or metastatic/recurrent GIST. METHODS: Between September 2009 and February 2014, patients with primarily unresectable or metastatic/recurrent GIST treated by a single medical team were recruited and considered for preoperative IM therapy. Re-examination was conducted regularly and abdominal enhanced CT data, blood biochemistry and responses to IM were recorded. RESULTS: A total of 18 patients were enrolled, including 13 with a primary tumor (7 stomach, 3 small bowel, 2 rectal and 1 pelvic tumor) and 5 with recurrent or metastatic GIST (2 with liver metastasis, 2 with anastomotic recurrence and 1 with pelvic GIST). The median follow-up time was 9.5 months (range of 3-63). The median tumor sizes before and after initiation of IM treatment were 9.1 cm and 6.0 cm (p = 0.003) based on the CT findings, respectively. All patients showed a decrease in tumor burden and the median tumor size reduction was 35%. Sixteen of the 18 patients showed a partial response to IM and two possessed stable disease. Nine of the 18 patients (50%) underwent surgical resection of primary or metastatic/recurrent tumors, with a median of 7 months of IM therapy. One case each of multivisceral resection and tumor recurrence were noted. CONCLUSIONS: IM as a preoperative therapy is feasible and safe for unresectable or metastatic/recurrent GIST that can effectively decrease tumor size, facilitating resection. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-11-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/96916 10.6061/clinics/2014(11)09 |
url |
https://www.revistas.usp.br/clinics/article/view/96916 |
identifier_str_mv |
10.6061/clinics/2014(11)09 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/96916/95996 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2015 Clinics info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2015 Clinics |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
dc.source.none.fl_str_mv |
Clinics; Vol. 69 No. 11 (2014); 758-762 Clinics; v. 69 n. 11 (2014); 758-762 Clinics; Vol. 69 Núm. 11 (2014); 758-762 1980-5322 1807-5932 reponame:Clinics instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Clinics |
collection |
Clinics |
repository.name.fl_str_mv |
Clinics - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||clinics@hc.fm.usp.br |
_version_ |
1800222761652584448 |